Investor Profile: AlbionVC — Thesis, Cheque Size & How to Apply

For founders weighing up AlbionVC funding, it helps to know exactly what this London institution looks for. Founded in 1996 by Patrick Reeve, a former Close Brothers corporate financier, AlbionVC describes itself as the technology investment arm of Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority. The firm's website states its focus plainly: it backs early-stage founders across deeptech, health, finance and intelligence, pairing long-term capital with hands-on scale-up expertise. With around £1 billion in assets under management, it is one of the most established early-stage investors in the UK.

Investment thesis: visionary UK founders at the inflexion point

AlbionVC's stated mission is to back companies that reshape entire industries, and to give them the long-term capital to do it. The firm concentrates on B2B software, digital health, fintech and deeptech, investing at the "inflexion point" — the stage where a company has proved its product and needs capital to scale. Its track record spans roughly three decades with more than 100 exits, and its listed VCT vehicles target dividends of around 5% of net asset value per year.

AlbionVC funding: sectors, stages and cheque size

AlbionVC invests primarily in UK-based companies at Series A and B, through both its venture funds and its six listed Venture Capital Trusts. The Albion VCTs hold total net assets of about £784 million across roughly 75 companies, with the Albion Enterprise VCT alone valued at £292.3 million as of 31 March 2026. The firm does not publish one fixed cheque range; investor directories list typical Series A/B investments at above €3 million, and the VCT vehicles routinely participate in follow-on rounds as companies scale.

Notable portfolio

AlbionVC's reputation rests on early conviction in companies that became category leaders. It led Quantexa's first round in 2017 alongside HSBC; the decision-intelligence company later raised a $175 million Series F in 2025 at a $2.6 billion valuation and now works with HSBC, BNY and Standard Chartered. Oviva, Europe's leading virtual clinic for weight-related diseases, has been backed since its 2016 seed round and has treated over a million patients. Other portfolio names include Elliptic (blockchain analytics), Gravitee (API management), Phasecraft (quantum algorithms), tem (AI-native energy trading, $75 million Series B in 2026 led by Lightspeed), Booking.com, and Egress, acquired by KnowBe4 in 2024 at over seven times cost.

Partners and team

Founder Patrick Reeve led the firm from its 1996 origins. Partners named across the firm's portfolio pages include Ed Lascelles — credited by the founders of Egress, Oviva and Elliptic — and Adam Chirkowski, who led the Phasecraft and tem investments. The firm operates from 1 Benjamin Street, Farringdon, London.

How to apply for funding

Founders can submit their pitch deck directly through the form linked on albion.vc ("Submit your pitch deck"). As with most VCs, a warm introduction via a portfolio founder or co-investor strengthens a cold submission. Expect rigorous questions on your route to product-market fit, unit economics, and why the UK's deeptech, health, fintech or intelligence ecosystems are the right launchpad.